Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Chief Scientific Officer | March 01, 2025 | March 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date March 01, 2025 · Filed March 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 265,662 |
Ending reported balance
After 2025-03-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-01 · Exercise / conversion · Acquired 50,000 · Balance 281,995 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Row 2 · 2025-03-01 · Exercise / conversion · Acquired 10,925 · Balance 292,920 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Row 3 · 2025-03-01 · Tax withholding · Disposed 27,258 · Balance 265,662 F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-01 · Exercise / conversion · Disposed 50,000 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 10,925 |
Reported balance
After 2025-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-03-01 · Exercise / conversion · Disposed 10,925 · Balance 10,925 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 193 |
Reported balance
Holding disclosure · report date 2025-03-01 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 193 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
F4: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 3, 2023 17:07 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $16.97 | $0.00 |
DisclosureSEC source: 0001209191-23-007023 · doc4.xml · derivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 16:57 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 5,000 | $15.88 | $79,411.50 |
DisclosureSEC source: 0001209191-22-061695 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,386 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.56 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 17, 2022 Filed Oct 19, 2022 16:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 5,000 | $15.98 | $79,907.50 |
DisclosureSEC source: 0001209191-22-054073 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,386 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 1, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.72 to $16.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 17:06 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 30,000 | $16.28 | $488,298.00 |
DisclosureSEC source: 0001209191-22-025032 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,386 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2022. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.84 to $16.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 16:53 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 27,165 | $15.71 | $426,802.90 |
DisclosureSEC source: 0001209191-22-018501 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,386 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2022 and March 2, 2022 pursuant to preexisting sell-to-cover elections. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.22 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · derivative · entry 9 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 02, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · nonDerivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · derivative · entry 8 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted stock units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · derivative · entry 7 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted stock units · Derivative | 43,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · derivative · entry 6 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,700 Underlying: Common Stock · 43,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 153,100 | $0.00 Strike: $14.94 | $0.00 |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · derivative · entry 5 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,100 Underlying: Common Stock · 153,100 shares Expires 2032-02-29 F2 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on March 1, 2023, subject to Reporting Person's continuous service as an officer with the issuer as of the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 18:11 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 13,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-015829 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 16:22 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 383 | $12.68 | $4,857.13 |
DisclosureSEC source: 0001209191-22-008860 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,301 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2022 pursuant to preexisting sell-to-cover elections. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:49 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 1,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006836 · doc4.xml · derivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vested on February 1, 2022. F2 · derivative.expiration_date: The shares underlying these restricted stock units vested on February 1, 2022. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:49 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 1,050 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-006836 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 17:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 2,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-054530 · doc4.xml · derivative · entry 4 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vested on September 1, 2021. F3 · derivative.expiration_date: The shares underlying these restricted stock units vested on September 1, 2021. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 17:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 1,041 | $17.22 | $17,926.02 |
DisclosureSEC source: 0001209191-21-054530 · doc4.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,634 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 17:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 2,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-054530 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 21:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 3,550 | $22.31 | $79,205.47 |
DisclosureSEC source: 0001209191-21-037478 · doc4.xml · nonDerivative · entry 3 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,342 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.03 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 21:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 18,240 | $21.50 | $392,231.14 |
DisclosureSEC source: 0001209191-21-037478 · doc4.xml · nonDerivative · entry 2 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,892 F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections. F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.03 to $22.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-037478 · doc4.xml · derivative · entry 5 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vested on June 1, 2021. F5 · derivative.expiration_date: The shares underlying these restricted stock units vested on June 1, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 21:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-037478 · doc4.xml · nonDerivative · entry 1 Monahan Joseph · CIK 0001861790 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.